$1.9bn raised for Bain Capital’s life sciences fund

Bain Capital’s life sciences arm has just finished raising $1.9bn for its third investment fund.

The fund also includes $300m from current and former partners of the Boston-based private equity firm, and it has begun searching for drug, biotech, and medical device companies where it can invest the money. The types of companies that the 16-person team at Bain Capital Life Sciences will target include, among others, those that need financing to complete clinical trials or a geographic expansion, and public companies whose stocks were beaten down by an unexpected event but still hold significant value.

This fund will be among the largest private equity funds in the life sciences sector; it follows a $720m fund, and a $1.1bn fund that Bain previously raised, and deployed in recent years. Some Boston-area recipients of these investments include Cerevel Therapeutics, Nuvalent, Amylyx Pharmaceuticals, and AavantiBio. Bain expects to place investments of $25 million to $100 million in size over the next four years with various life sciences companies. “It’s a great time to be investing in life sciences,” said Adam Koppel, managing director at Bain Capital Life Sciences.

Join 120,000 other PE professionals and subscribe to our weekly newsletter
Learn More

Subscribe to our Newsletter to increase your edge. Don’t worry about the news anymore, through our newsletter you’ll receive weekly access to what is happening. Join 120,000 other PE professionals today.

Bain Capital is one of the world’s leading private multi-asset alternative investment firms with approximately $140bn in assets under management that creates lasting impact for their investors, teams, businesses and the communities in which they live. Founded in 1984, Bain Capital pioneered a consulting-based approach to private equity investing, partnering closely with management teams to offer the insights that challenge conventional thinking, build great businesses, and improve operations. Over time, Bain Capital have organically expanded this approach across asset classes to build one of the strongest alternative asset platforms in the world.

Today, the teams strive to create value through private equity, public equity, fixed income, credit, venture capital, and real estate investments across multiple sectors, industries, and geographies. Bain Capital believes that our people, and the shared values we’ve espoused since our founding remain the core of our competitive advantage. This has empowered Bain Capital to deliver an enduring impact to a diverse group of investors including pensions, endowments, foundations, and individuals.

Source: Boston Globe

Can’t stop reading? Read more